Iridex 532 and Iridex 577 Lasers Launched in United States

Iridex announced the United States launch of its next-generation platform Iridex 532 and Iridex 577 lasers.

According to the company, both lasers harness multiple treatment modes including continuous-wave and the company’s MicroPulse technology and an intuitive touchscreen interface providing a wide range of clinical control options and features for the treatment of glaucoma and diabetic macular edema and other retinal diseases. The MicroPulse technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions.

The company will showcase the devices at the Hawaiian Eye and Retina 2024 Meeting held January 13-19 in Wailea, Hawaii.

As outlined in the company’s press release, features of the Iridex 532 and Iridex 577 lasers include the following:

• Comprehensive Treatment Reports—Physicians can create detailed reports of treatment parameters for every procedure. These reports can be easily managed and downloaded to a USB drive.
• Configurable Preset Filters—Customizable filters, allowing for simple program management and selection via the new preset management tool enabling customizable selections by procedure and by individual doctor.
• Enhanced User Experience—The multifunctional single control knob ensures simplified console navigation. Additionally, the 7-inch high-resolution touchscreen display provide an interactive experience, allowing physicians to navigate seamlessly between options.
• MicroPulse Laser Applications—MicroPulse, a laser delivery modality that adds fine control of photothermal effects in laser photocoagulation, is a tissue-sparing solution for the treatment of retinal diseases and glaucoma.

Sam Mansour, MD, Medical Director of the Virginia Retina Center, previewed the new Iridex 577 nm laser.

“I was very pleased with the compact design and intuitive user interface,” commented Dr. Mansour in the company’s press release. “Its treatment-session recordings enhance therapeutic tracking from subsequent laser sessions, and the rapid maneuverability between console menus will undoubtedly improve patient flow. Having used Iridex laser systems for 30 years, I can attest to the highly dependable quality of their products.”

David Bruce, President and CEO of Iridex Corporation, stated in the press release, “The launch of the new Iridex 532 and Iridex 577 Lasers stands as a testament to our 3-year heritage of providing advanced laser solutions to ophthalmologists worldwide. These innovations mark a pivotal moment for us, blending modern technology with user-centric design to ensure optimized treatments for retinal disorders and glaucoma.”